Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 70

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 8
Chunk 70
---
 partners, and the Company and certain of its former employees, alleging violations of the False Claims Act. The government declined to intervene in the case. The Company was not aware of the complaint until after it was unsealed. On April 16, 2025, the Company was served with the complaint. 

13.SEGMENT REPORTING AND RELATED INFORMATION

The Company has identified the President and Chief Executive Officer as the Chief Operating Decision Maker (the "CODM") . The CODM regularly reviews consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Accordingly, the Company has determined that it operates as a single operating segment.

The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses and other segment expenses presented to the CODM are at the same level as presented in Consolidated Statement Operations in these financial statements. 

14.SUPPLEMENTAL CASH FLOW INFORMATION

The Company's supplemental cash flow information for the three months ended March 31, 2025 and 2024 are as follows:Three Months Ended March 31,(in millions)20252024Cash paid for income taxes$0.3 $— Cash paid for interest0.5 0.2 Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets$1.2 $(0.3)Operating lease liabilities(1.2)(3.1)Purchases of property, plant, and equipment and capitalization of internal-use software in accounts payable and accrued liabilities4.2 4.5 

17

Table of Contents

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.March 31,(in millions)20252024Cash and cash equivalents$91.8 $96.9 Restricted cash9.2 8.7 Total cash, cash equivalents, and restricted cash$101.0 $105.6 

15. ACCUMULATED OTHER COMPREHENSIVE LOSS

The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The